GYRE — GYRE THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1124105 ·
Last close
$7.35
Market Cap
$779.35M
52W High
$9.42
52W Low
$5.44
ADV30
140,230
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 29,105,000 | 26,896,000 | -13,861,000 | -10,605,000 | 199,255,000 | 43,287,000 | 56,766,000 |
| Mar 2026 | 22,519,000 | 21,292,000 | -6,802,000 | -8,691,000 | 162,015,000 | 37,501,000 | 25,030,000 |
| Dec 2025 | 37,195,000 | 35,452,000 | 120,000 | -1,723,000 | 166,132,000 | 37,070,000 | 23,850,000 |
| Sep 2025 | 30,564,000 | 28,936,000 | 6,926,000 | 3,610,000 | 159,384,000 | 40,402,000 | 21,969,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,319,000
Investing CF
$-5,496,000
Financing CF
$23,055,000
CapEx
$-1,285,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.09
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-77,667,000
Inventory
$11,352,000
Receivables
$26,810,000
ST Investments
$12,307,000
EBIT TTM
$2,416,000
Pretax Income TTM
$564,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$109,818,000
EBITDA
$-12,131,000
Free Cash Flow
$1,875,250
Enterprise Value
$699,220,224
Total Cash
$74,796,000
Total Debt
$3,418,000
Shares Out
106,033,763
Trailing EPS
$-0.21
Book Value
$1.02
ROE
-17.4%
ROA
-5.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 116,588,000 | 11,491,000 | 5,027,000 | 166,132,000 | 23,850,000 | 106,031,000 | 1,010,000 |
| Dec 2024 | 105,757,000 | 16,229,000 | 12,085,000 | 125,406,000 | 27,004,000 | 63,319,000 | -3,641,000 |
| Dec 2023 | 113,450,000 | 19,213,000 | -92,933,000 | 116,539,000 | 102,590,000 | -15,828,000 | 25,892,000 |
| Dec 2022 | 102,290,000 | 9,203,000 | 2,302,000 | 84,753,000 | 12,536,000 | 42,522,000 | 10,677,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.06
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $7.47 · call volume: 3 · put volume: 0
Expected Move to 2026-10-16:
±$4.90
(65.60%) —
implied range
$2.57 –
$12.37
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMMX | Immix Biopharma, Inc. | $784.79M | $10.97 | — |
| OLMA | Olema Pharmaceuticals, Inc. | $765.60M | $8.75 | — |
| OBX | Obsidian Therapeutics, Inc. | $794.40M | $12.86 | — |
| IVA | Inventiva S.A. | $796.06M | $3.37 | — |
| IVEVF | Inventiva S.A. | $760.63M | $3.22 | — |
News headlines (Yahoo Finance, 1h cache)
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-03 11:00 · Yahoo
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates
2026-08-07 12:20 · Yahoo
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
2026-08-07 11:00 · Yahoo
Gyre Therapeutics Appoints Three New Members to its Board of Directors
2026-07-16 20:05 · Yahoo
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
2026-05-12 20:05 · Yahoo
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 11:45 · Yahoo
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
2026-05-07 10:00 · Yahoo
US High Growth Tech Stocks To Watch
2026-04-27 17:38 · Yahoo
New Strong Sell Stocks for May 27th
2026-05-27 12:18 · Yahoo
Exploring Three High Growth Tech Stocks In The US Market
2026-03-27 17:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.